We are live on ! Find out more
CBPO

China Biologic Products Holdings, Inc.
CBPO

Delisted

CBPO was delisted on the 20th of April, 2021.

88 hedge funds and large institutions have $1.77B invested in China Biologic Products Holdings, Inc. in 2019 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 23 increasing their positions, 25 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

189% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 9

25% more capital invested

Capital invested by funds: $1.42B → $1.77B (+$352M)

24% more funds holding

Funds holding: 7188 (+17)

8% less repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 25

29% less call options, than puts

Call options by funds: $22.8M | Put options by funds: $32.2M

33% less funds holding in top 10

Funds holding in top 10: 64 (-2)

Holders
88
Holders Change
+17
Holders Change %
+23.94%
% of All Funds
1.93%
Holding in Top 10
4
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-33.33%
% of All Funds
0.09%
New
26
Increased
23
Reduced
25
Closed
9
Calls
$22.8M
Puts
$32.2M
Net Calls
-$9.45M
Net Calls Change
-$19.6M
Name Holding Trade Value Shares
Change
Change in
Stake
State Street
26
State Street
Massachusetts
$6.18M +$1.89M +19,029 +54%
California Public Employees Retirement System
27
California Public Employees Retirement System
California
$5.87M +$1.99M +20,047 +64%
Goldman Sachs
28
Goldman Sachs
New York
$5.37M -$664K -6,682 -12%
PPA
29
Parametric Portfolio Associates
Washington
$4.78M -$219K -2,200 -5%
Northern Trust
30
Northern Trust
Illinois
$4.47M +$568K +5,714 +17%
Invesco
31
Invesco
Georgia
$4.34M -$481K -4,842 -11%
Citadel Advisors
32
Citadel Advisors
Florida
$3.89M +$3.05M +30,692 +923%
Charles Schwab
33
Charles Schwab
California
$3.76M +$3.27M +32,880 New
MAM
34
Myriad Asset Management
Hong Kong
$3.74M +$3.25M +32,657 New
DI
35
Dalton Investments
Nevada
$3.67M -$6.14M -61,800 -66%
Citigroup
36
Citigroup
New York
$3.43M
Geode Capital Management
37
Geode Capital Management
Massachusetts
$3.2M -$5.27K -53 -0.2%
MWNA
38
Marshall Wace North America
New York
$2.9M +$2.52M +25,304 New
Voloridge Investment Management
39
Voloridge Investment Management
Florida
$2.73M +$2.37M +23,849 New
Robeco Institutional Asset Management
40
Robeco Institutional Asset Management
Netherlands
$2.46M +$2.14M +21,503 New
PIM
41
Paradice Investment Management
Colorado
$2.42M +$1.72M +17,258 +441%
Point72 Asset Management
42
Point72 Asset Management
Connecticut
$2.07M -$4.96M -49,915 -73%
Bank of New York Mellon
43
Bank of New York Mellon
New York
$1.93M -$45.3K -456 -3%
Renaissance Technologies
44
Renaissance Technologies
New York
$1.72M +$587K +5,900 +65%
PNC Financial Services Group
45
PNC Financial Services Group
Pennsylvania
$1.55M +$1.35M +13,576 New
ACM
46
AlphaCrest Capital Management
New York
$1.53M +$1.33M +13,400 New
AIA
47
AGF Investments America
Ontario, Canada
$1.39M +$1.21M +12,123 New
OAC
48
OMERS Administration Corp
Ontario, Canada
$1.3M +$1.13M +11,400 New
ProShare Advisors
49
ProShare Advisors
Maryland
$1.19M -$100K -1,007 -9%
CS
50
Credit Suisse
Switzerland
$1.06M -$2.8M -28,138 -75%

CBPO Hedge Fund Activity: Q3 2019 in Review

88 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in China Biologic Products Holdings, Inc. (CBPO) for Q3 2019, worth a combined $1.77B — up 25% from $1.42B a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new CBPO positions and 9 closed out — a net gain of 17 holders — while 23 added to existing stakes and 25 trimmed.

The largest buyer was Capital Research Global Investors, adding an estimated $83.8M. The largest seller was Capital World Investors, exiting entirely with an estimated $32.7M sold.

  • 88 institutional investors held China Biologic Products Holdings, Inc. (CBPO) as of Q3 2019, up from 71 in Q2 2019.
  • Funds reported $1.77B of China Biologic Products Holdings, Inc. stock for Q3 2019, up 25% quarter-over-quarter.
  • 26 funds opened new China Biologic Products Holdings, Inc. positions in Q3 2019 and 9 closed out, a net change of +17 holders.
  • The largest China Biologic Products Holdings, Inc. buyer in Q3 2019 was Capital Research Global Investors, an estimated $83.8M added.
  • The largest China Biologic Products Holdings, Inc. seller in Q3 2019 was Capital World Investors, an estimated $32.7M sold.

Based on aggregated 13F filings for Q3 2019.